{"count": 6, "results": [{"_id": "34555978", "pmid": 34555978, "title": "Emerging agents for the treatment and prevention of stroke: progress in clinical trials.", "journal": "Expert Opin Investig Drugs", "authors": ["Safouris A", "Magoufis G", "Tsivgoulis G"], "date": "2021-10-01T00:00:00Z", "doi": "10.1080/13543784.2021.1985463", "meta_date_publication": "2021 Oct", "meta_volume": "30", "meta_issue": "10", "meta_pages": "1025-1035", "score": 50225.086, "text_hl": "ABBREVIATIONS: IVT: intravenous thrombolysis; RCTs: randomized-controlled clinical trials; TNK: Tenecteplase; @DISEASE_COVID_19 @DISEASE_MESH:D000086382 @@@COVID-19@@@: @DISEASE_COVID_19 @DISEASE_MESH:D000086382 @@@Coronavirus 2019 Disease@@@; EXTEND-IA TNK: The Tenecteplase versus Alteplase Before Endovascular Therapy for @DISEASE_Cerebral_Infarction @DISEASE_MESH:D002544 @@@Ischemic Stroke@@@ trial; @DISEASE_Androgen_Insensitivity_Syndrome @DISEASE_MESH:D013734 @@@AIS@@@: @DISEASE_Ischemic_Stroke @DISEASE_MESH:D000083242 @@@acute ischemic stroke@@@; NNT: number needed to treat; MT: mechanical thrombectomy; sICH: symptomatic @DISEASE_Intracranial_Hemorrhages @DISEASE_MESH:D020300 @@@intracranial hemorrhage@@@; mRS: modified Rankin Scale; AHA/@CHEMICAL_Aspirin @CHEMICAL_MESH:D001241 @@@ASA@@@: American Heart Association/American @DISEASE_Stroke @DISEASE_MESH:D020521 @@@Stroke@@@ Association; ESO: European @DISEASE_Stroke @DISEASE_MESH:D020521 @@@Stroke@@@ Organization; NA-1: @CHEMICAL_Tat_NR2B9c @CHEMICAL_MESH:C542597 @@@Nerinetide@@@; ENACT: Evaluating Neuroprotection in @DISEASE_Aneurysm @DISEASE_MESH:D000783 @@@Aneurysm@@@ Coiling Therapy; CTA: CT angiography; @DISEASE_Ischemic_Attack_Transient @DISEASE_MESH:D002546 @@@TIA@@@: @DISEASE_Ischemic_Attack_Transient @DISEASE_MESH:D002546 @@@transient ischemic attack@@@; CHANCE: @CHEMICAL_Clopidogrel @CHEMICAL_MESH:D000077144 @@@Clopidogrel@@@ in High-risk @SPECIES_9606 @@@patients@@@ with Acute Non-disabling @DISEASE_Cerebrovascular_Disorders @DISEASE_MESH:D002561 @@@Cerebrovascular Events@@@; LOF: loss-of-function; PRINCE: Platelet Reactivity in Acute Nondisabling @DISEASE_Cerebrovascular_Disorders @DISEASE_MESH:D002561 @@@Cerebrovascular Events@@@; THALES: Acute @DISEASE_Stroke @DISEASE_MESH:D020521 @@@Stroke@@@ or @DISEASE_Ischemic_Attack_Transient @DISEASE_MESH:D002546 @@@Transient Ischemic Attack@@@ Treated with @CHEMICAL_Ticagrelor @CHEMICAL_MESH:D000077486 @@@Ticagrelor@@@ and @CHEMICAL_Aspirin @CHEMICAL_MESH:D001241 @@@ASA@@@ [@CHEMICAL_Aspirin @CHEMICAL_MESH:D001241 @@@acetylsalicylic acid@@@] for Prevention of @DISEASE_Stroke @DISEASE_MESH:D020521 @@@Stroke@@@ and @DISEASE_Death @DISEASE_MESH:D003643 @@@Death@@@; CHANCE-2: @CHEMICAL_Clopidogrel @CHEMICAL_MESH:D000077144 @@@Clopidogrel@@@ With @CHEMICAL_Aspirin @CHEMICAL_MESH:D001241 @@@Aspirin@@@ in High-risk @SPECIES_9606 @@@Patients@@@ With Acute Non-disabling @DISEASE_Cerebrovascular_Disorders @DISEASE_MESH:D002561 @@@Cerebrovascular Events@@@ II; FXI: Factor XI; PACIFIC-@DISEASE_Stroke @DISEASE_MESH:D020521 @@@STROKE@@@: Program of Anticoagulation via Inhibition of FXIa by the Oral Compound BAY 2433334-NonCardioembolic @DISEASE_Stroke @DISEASE_MESH:D020521 @@@Stroke@@@ study; COMPASS: Cardiovascular Outcomes for People Using Anticoagulation Strategies; CANTOS-ICAD: Combination Antithrombotic Treatment for Prevention of Recurrent @DISEASE_Cerebral_Infarction @DISEASE_MESH:D002544 @@@Ischemic Stroke@@@ in Intracranial Atherosclerotic Disease; SAMMPRIS: Stenting and Aggressive Medical Therapy for Preventing Recurrent @DISEASE_Stroke @DISEASE_MESH:D020521 @@@Stroke@@@ in @DISEASE_Constriction_Pathologic @DISEASE_MESH:D003251 @@@Intracranial Stenosis@@@; WASID: @CHEMICAL_Warfarin @CHEMICAL_MESH:D014859 @@@Warfarin@@@-@CHEMICAL_Aspirin @CHEMICAL_MESH:D001241 @@@Aspirin@@@ Symptomatic @DISEASE_Intracranial_Arterial_Diseases @DISEASE_MESH:D020765 @@@Intracranial Disease@@@; SPARCL: @DISEASE_Stroke @DISEASE_MESH:D020521 @@@Stroke@@@ Prevention by Aggressive Reduction in @CHEMICAL_Cholesterol @CHEMICAL_MESH:D002784 @@@Cholesterol@@@ Levels; LDL-C: low-density lipoprotein cholesterol; TST: Treat @DISEASE_Stroke @DISEASE_MESH:D020521 @@@Stroke@@@ to Target; IMPROVE-IT: Improved Reduction of Outcomes: @<m>CHEMICAL_Ezetimibe_Simvastatin_Drug_Combination</m> @CHEMICAL_MESH:D000069499 @@@Vytorin@@@ Efficacy International Trial; @GENE_PCSK9 @GENE_255738 @@@PCSK9@@@: proprotein convertase subtilisin-kexin type 9; FOURIER: Further Cardiovascular Outcomes Research with @GENE_PCSK9 @GENE_255738 @@@PCSK9@@@ Inhibition in Subjects with Elevated Risk; CLEAR: @CHEMICAL_Cholesterol @CHEMICAL_MESH:D002784 @@@Cholesterol@@@ Lowering via @CHEMICAL_8_hydroxy_2_2_14_14_tetramethylpentadecanedioic_acid @CHEMICAL_MESH:C581236 @@@Bempedoic acid@@@, an ACL-inhibiting Regimen; REDUCE-IT: Reduction of Cardiovascular Events With EPA Intervention Trial; STRENGTH: Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk @SPECIES_9606 @@@PatienTs@@@ With @DISEASE_Hypertriglyceridemia @DISEASE_MESH:D015228 @@@Hypertriglyceridemia@@@; ACCORD: Action to Control Cardiovascular Risk in @<m>DISEASE_Diabetes_Mellitus</m> @DISEASE_MESH:D003920 @@@Diabetes@@@; ADVANCE: Action in @<m>DISEASE_Diabetes_Mellitus</m> @DISEASE_MESH:D003920 @@@Diabetes@@@ and @DISEASE_Vascular_Diseases @DISEASE_MESH:D014652 @@@Vascular Disease@@@: Preterax and @CHEMICAL_Gliclazide @CHEMICAL_MESH:D005907 @@@Diamicron@@@ Modified Release Controlled Evaluation; VADT: Veterans Affairs @<m>DISEASE_Diabetes_Mellitus</m> @DISEASE_MESH:D003920 @@@Diabetes@@@ Trial; GLP-1R: @GENE_GLP1R @GENE_2740 @@@Glucagon-like peptide-1 receptor@@@; @GENE_SLC5A2 @GENE_6524 @@@SGLT2@@@: sodium-glucose cotransporter 2; CONVINCE: COlchicine for preventioN of Vascular Inflammation in Non-CardioEmbolic @DISEASE_Stroke @DISEASE_MESH:D020521 @@@stroke@@@; PROBE: Prospective Randomized Open-label Blinded Endpoint assessment.", "citations": {"NLM": "Safouris A, Magoufis G, Tsivgoulis G. Emerging agents for the treatment and prevention of stroke: progress in clinical trials. Expert Opin Investig Drugs. 2021 Oct;30(10):1025-1035. PMID: 34555978", "BibTeX": "@article{34555978, title={Emerging agents for the treatment and prevention of stroke: progress in clinical trials.}, author={Safouris A and Magoufis G and Tsivgoulis G}, journal={Expert Opin Investig Drugs}, volume={30}, number={10}, pages={1025-1035}}"}}, {"_id": "27036394", "pmid": 27036394, "title": "Effects of Extended-Release Niacin Added to Simvastatin/Ezetimibe on Glucose and Insulin Values in AIM-HIGH.", "journal": "Am J Med", "authors": ["Goldberg RB", "Bittner VA", "Dunbar RL", "Fleg JL", "Grunberger G", "Guyton JR", "Leiter LA", "McBride R", "Robinson JG", "Simmons DL", "Wysham C", "Xu P", "Boden WE"], "date": "2016-07-01T00:00:00Z", "doi": "10.1016/j.amjmed.2016.02.039", "meta_date_publication": "2016 Jul", "meta_volume": "129", "meta_issue": "7", "meta_pages": "753.e13-22", "score": 50064.934, "text_hl": "CONCLUSIONS: The addition of ERN to @<m>CHEMICAL_Ezetimibe_Simvastatin_Drug_Combination</m> @CHEMICAL_MESH:D000069499 @@@simvastatin/ezetimibe@@@ had marginal effects on glycemia in those with @<m>DISEASE_Diabetes_Mellitus</m> @DISEASE_MESH:D003920 @@@diabetes@@@ at baseline, and there was a trend toward increased development of new-onset @<m>DISEASE_Diabetes_Mellitus</m> @DISEASE_MESH:D003920 @@@diabetes@@@. ", "citations": {"NLM": "Goldberg RB, Bittner VA, Dunbar RL, Fleg JL, Grunberger G, Guyton JR, Leiter LA, McBride R, Robinson JG, Simmons DL, Wysham C, Xu P, Boden WE. Effects of Extended-Release Niacin Added to Simvastatin/Ezetimibe on Glucose and Insulin Values in AIM-HIGH. Am J Med. 2016 Jul;129(7):753.e13-22. PMID: 27036394", "BibTeX": "@article{27036394, title={Effects of Extended-Release Niacin Added to Simvastatin/Ezetimibe on Glucose and Insulin Values in AIM-HIGH.}, author={Goldberg RB and Bittner VA and Dunbar RL and Fleg JL and Grunberger G and Guyton JR and Leiter LA and McBride R and Robinson JG and Simmons DL and Wysham C and Xu P and Boden WE}, journal={Am J Med}, volume={129}, number={7}, pages={753.e13-22}}"}}, {"_id": "20152243", "pmid": 20152243, "title": "Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia.", "journal": "Am J Cardiol", "authors": ["Fazio S", "Guyton JR", "Polis AB", "Adewale AJ", "Tomassini JE", "Ryan NW", "Tershakovec AM"], "date": "2010-02-15T00:00:00Z", "doi": "10.1016/j.amjcard.2009.10.001", "meta_date_publication": "2010 Feb 15", "meta_volume": "105", "meta_issue": "4", "meta_pages": "487-94", "score": 50064.848, "text_hl": "The occurrence of new-onset @<m>DISEASE_Diabetes_Mellitus</m> @DISEASE_MESH:D003920 @@@diabetes@@@ was 3.1% for the @<m>CHEMICAL_Ezetimibe_Simvastatin_Drug_Combination</m> @CHEMICAL_MESH:D000069499 @@@E/S@@@ and 4.9% for the @<m>CHEMICAL_Ezetimibe_Simvastatin_Drug_Combination</m> @CHEMICAL_MESH:D000069499 @@@E/S@@@ plus @CHEMICAL_Niacin @CHEMICAL_MESH:D009525 @@@niacin@@@ group. ", "citations": {"NLM": "Fazio S, Guyton JR, Polis AB, Adewale AJ, Tomassini JE, Ryan NW, Tershakovec AM. Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia. Am J Cardiol. 2010 Feb 15;105(4):487-94. PMID: 20152243", "BibTeX": "@article{20152243, title={Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia.}, author={Fazio S and Guyton JR and Polis AB and Adewale AJ and Tomassini JE and Ryan NW and Tershakovec AM}, journal={Am J Cardiol}, volume={105}, number={4}, pages={487-94}}"}}, {"_id": "21291725", "pmid": 21291725, "title": "Effect of ezetimibe/simvastatin versus atorvastatin or rosuvastatin on modifying lipid profiles in patients with diabetes, metabolic syndrome, or neither: Results of two subgroup analyses.", "journal": "J Clin Lipidol", "authors": ["Abate N", "Catapano AL", "Ballantyne CM", "Davidson MH", "Polis A", "Smugar SS", "Tershakovec AM"], "date": "2008-04-01T00:00:00Z", "doi": "10.1016/j.jacl.2008.02.002", "meta_date_publication": "2008 Apr", "meta_volume": "2", "meta_issue": "2", "meta_pages": "91-105", "score": 50063.566, "text_hl": "OBJECTIVE: To compare the effects of @CHEMICAL_Ezetimibe @CHEMICAL_MESH:D000069438 @@@ezetimibe@@@/@CHEMICAL_Simvastatin @CHEMICAL_MESH:D019821 @@@simvastatin@@@ (@<m>CHEMICAL_Ezetimibe_Simvastatin_Drug_Combination</m> @CHEMICAL_MESH:D000069499 @@@E/S@@@) combination therapy, @CHEMICAL_Atorvastatin @CHEMICAL_MESH:D000069059 @@@atorvastatin@@@, and @CHEMICAL_Rosuvastatin_Calcium @CHEMICAL_MESH:D000068718 @@@rosuvastatin@@@ in @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Diabetes_Mellitus</m> @DISEASE_MESH:D003920 @@@DM@@@, @DISEASE_Metabolic_Syndrome @DISEASE_MESH:D024821 @@@MS@@@ without @<m>DISEASE_Diabetes_Mellitus</m> @DISEASE_MESH:D003920 @@@DM@@@, or neither disease. ", "citations": {"NLM": "Abate N, Catapano AL, Ballantyne CM, Davidson MH, Polis A, Smugar SS, Tershakovec AM. Effect of ezetimibe/simvastatin versus atorvastatin or rosuvastatin on modifying lipid profiles in patients with diabetes, metabolic syndrome, or neither: Results of two subgroup analyses. J Clin Lipidol. 2008 Apr;2(2):91-105. PMID: 21291725", "BibTeX": "@article{21291725, title={Effect of ezetimibe/simvastatin versus atorvastatin or rosuvastatin on modifying lipid profiles in patients with diabetes, metabolic syndrome, or neither: Results of two subgroup analyses.}, author={Abate N and Catapano AL and Ballantyne CM and Davidson MH and Polis A and Smugar SS and Tershakovec AM}, journal={J Clin Lipidol}, volume={2}, number={2}, pages={91-105}}"}}, {"_id": "29263150", "pmid": 29263150, "title": "Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).", "journal": "Circulation", "authors": ["Giugliano RP", "Cannon CP", "Blazing MA", "Nicolau JC", "Corbalán R", "Špinar J", "Park JG", "White JA", "Bohula EA", "Braunwald E", "IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators"], "date": "2018-04-10T00:00:00Z", "doi": "10.1161/CIRCULATIONAHA.117.030950", "meta_date_publication": "2018 Apr 10", "meta_volume": "137", "meta_issue": "15", "meta_pages": "1571-1582", "score": 50060.6, "text_hl": "@<m>CHEMICAL_Ezetimibe_Simvastatin_Drug_Combination</m> @CHEMICAL_MESH:D000069499 @@@E/S@@@ achieved a significantly lower median time-weighted average low-density lipoprotein cholesterol compared with placebo/@CHEMICAL_Simvastatin @CHEMICAL_MESH:D019821 @@@simvastatin@@@, irrespective of @<m>DISEASE_Diabetes_Mellitus</m> @DISEASE_MESH:D003920 @@@DM@@@ (@<m>DISEASE_Diabetes_Mellitus</m> @DISEASE_MESH:D003920 @@@DM@@@: 49 versus 67 mg/dL; no @<m>DISEASE_Diabetes_Mellitus</m> @DISEASE_MESH:D003920 @@@DM@@@: 55 versus 71 mg/dL; both P<0.001). ", "citations": {"NLM": "Giugliano RP, Cannon CP, Blazing MA, Nicolau JC, Corbalán R, Špinar J, Park JG, White JA, Bohula EA, Braunwald E, IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 2018 Apr 10;137(15):1571-1582. PMID: 29263150", "BibTeX": "@article{29263150, title={Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).}, author={Giugliano RP and Cannon CP and Blazing MA and Nicolau JC and Corbalán R and Špinar J and Park JG and White JA and Bohula EA and Braunwald E and IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators}, journal={Circulation}, volume={137}, number={15}, pages={1571-1582}}"}}, {"_id": "24720535", "pmid": 24720535, "title": "Lipid-lowering treatment and inflammatory mediators in diabetes and chronic kidney disease.", "journal": "Eur J Clin Invest", "authors": ["Almquist T", "Jacobson SH", "Mobarrez F", "Näsman P", "Hjemdahl P"], "date": "2014-01-01T00:00:00Z", "doi": "10.1111/eci.12230", "meta_date_publication": "2014", "meta_volume": "44", "meta_issue": "3", "meta_pages": "276-84", "score": 50053.168, "text_hl": "LLT with @CHEMICAL_Sulfur @CHEMICAL_MESH:D013455 @@@S@@@ and @<m>CHEMICAL_Ezetimibe_Simvastatin_Drug_Combination</m> @CHEMICAL_MESH:D000069499 @@@S+E@@@ reduced @GENE_CCL2 @GENE_6347 @@@MCP-1@@@ levels (P < 0 01 by anova) and @GENE_IFNG @GENE_3458 @@@IFNgamma@@@ levels (P < 0 01) in @<m>DISEASE_Diabetes_Mellitus</m> @DISEASE_MESH:D003920 @@@DM@@@-@DISEASE_Renal_Insufficiency_Chronic @DISEASE_MESH:D051436 @@@CKD@@@ @SPECIES_9606 @@@patients@@@ but not in @<m>DISEASE_Diabetes_Mellitus</m> @DISEASE_MESH:D003920 @@@DM@@@-only @SPECIES_9606 @@@patients@@@. ", "citations": {"NLM": "Almquist T, Jacobson SH, Mobarrez F, Näsman P, Hjemdahl P. Lipid-lowering treatment and inflammatory mediators in diabetes and chronic kidney disease. Eur J Clin Invest. 2014;44(3):276-84. PMID: 24720535", "BibTeX": "@article{24720535, title={Lipid-lowering treatment and inflammatory mediators in diabetes and chronic kidney disease.}, author={Almquist T and Jacobson SH and Mobarrez F and Näsman P and Hjemdahl P}, journal={Eur J Clin Invest}, volume={44}, number={3}, pages={276-84}}"}}]}